Sabah Oney

Sabah Oney, CEO of Dispatch Biotherapeutics, specializes in engineered CAR-T cell therapies targeting solid tumors. In the discussion, she highlights the challenges of identifying unique cancer antigens and the use of oncolytic viruses to improve treatment efficacy. Oney shares innovative strategies for reprogramming CAR-T cells and enhancing the tumor microenvironment. She also emphasizes the importance of mission-driven leadership and collaboration within biotech, showcasing how a values-driven team can make breakthroughs in cancer research.